News | November 07, 2024
Mitsui Chemicals invests in clinical kidney disease drug developer Rege Nephro
The company uses iPS cells to develop treatments for diseases relating to the kidney
The company uses iPS cells to develop treatments for diseases relating to the kidney
The US District Court of New Jersey decided to grant a preliminary injunction delaying the launch of LEQSELVI
The partnership emphasises the introduction of renewable, bio-based materials into existing plastic applications to help reduce fossil resource dependency
The inspection concluded with the issuance of Form 483 with four observations which are procedural in nature
CMG1A46 is an investigational T cell-engager with potential to deeply deplete uncontrolled B cells present in autoimmune diseases such as lupus
This is in pursuance to the announcement made in the Union Budget for the year 2024-25 exempting these three anti-cancer medicines from customs duty
The workshop aimed to equip medicos with the necessary skills & knowledge to leverage AI's transformative power
Potential to optimize and build on the synergies in commercial operations, distribution, manufacturing, supply chain etc.
Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and commercial antibody supply of a new ADC
Silica is a proven and highly effective anti-caking agent that has been used for decades
Subscribe To Our Newsletter & Stay Updated
